Kazia Therapeutics Ltd
KZIA5.790USD
+0.170+3.02%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
46.87MMarket Cap
LossP/E TTM
More Details of Kazia Therapeutics Ltd Company
Kazia Therapeutics Limited is an oncology-focused drug development company. The Company operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. It is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. It designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.
Kazia Therapeutics Ltd Info
Ticker SymbolKZIA
Company nameKazia Therapeutics Ltd
IPO dateSep 01, 1994
CEOFriend (John E)
Number of employees- -
Security typeDepository Receipt
Fiscal year-endSep 01
AddressThree International Towers Level 24,
CitySYDNEY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryAustralia
Postal code2000
Phone1161298780088
Websitehttps://www.kaziatherapeutics.com/
Ticker SymbolKZIA
IPO dateSep 01, 1994
CEOFriend (John E)
Company Executives of Kazia Therapeutics Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Steven Roy Stent (Steve) Coffey
Mr. Steven Roy Stent (Steve) Coffey
Non-Executive Director
Non-Executive Director
1.98K
+1983.00%
Mr. Bryce Carmine
Mr. Bryce Carmine
Non-Executive Independent Director
Non-Executive Independent Director
1.71K
+1713.00%
Ms. Anna Sandham
Ms. Anna Sandham
Company Secretary
Company Secretary
--
--
Ms. Ebru Davidson
Ms. Ebru Davidson
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Justine R. Stehn, Ph.D.
Dr. Justine R. Stehn, Ph.D.
Director - ATM Program
Director - ATM Program
--
--
Stephen Palmer
Stephen Palmer
Program Director - Degenerative Diseases
Program Director - Degenerative Diseases
--
--
Lilischkis Ron Kimberley
Lilischkis Ron Kimberley
Clinical & Regulatory Affairs Manager
Clinical & Regulatory Affairs Manager
--
--
Mr. Peng K. Leong, Ph.D.
Mr. Peng K. Leong, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Dr. John E. Friend, M.D.
Dr. John E. Friend, M.D.
Interim Executive Chairman of the Board, Chief Executive Officer, Managing Director
Interim Executive Chairman of the Board, Chief Executive Officer, Managing Director
--
--
Ms. Karen Krumeich
Ms. Karen Krumeich
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Steven Roy Stent (Steve) Coffey
Mr. Steven Roy Stent (Steve) Coffey
Non-Executive Director
Non-Executive Director
1.98K
+1983.00%
Mr. Bryce Carmine
Mr. Bryce Carmine
Non-Executive Independent Director
Non-Executive Independent Director
1.71K
+1713.00%
Ms. Anna Sandham
Ms. Anna Sandham
Company Secretary
Company Secretary
--
--
Ms. Ebru Davidson
Ms. Ebru Davidson
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Justine R. Stehn, Ph.D.
Dr. Justine R. Stehn, Ph.D.
Director - ATM Program
Director - ATM Program
--
--
Stephen Palmer
Stephen Palmer
Program Director - Degenerative Diseases
Program Director - Degenerative Diseases
--
--
Revenue Breakdown
Currency: USDUpdated: Tue, Mar 4
Currency: USDUpdated: Tue, Mar 4
FY2022
FY2021
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
Sweden (Country)
0.00
0.00%
China (Country)
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Feb 1
Updated: Sun, Feb 1
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Lynwood Capital Management Inc.
5.74%
Chernett (Jorey)
1.28%
Dauntless Investment Group, LLC
1.10%
Westside Investment Management, LLC
0.29%
Alumni Capital Management LLC
0.26%
Other
91.33%
Shareholders
Shareholders
Proportion
Lynwood Capital Management Inc.
5.74%
Chernett (Jorey)
1.28%
Dauntless Investment Group, LLC
1.10%
Westside Investment Management, LLC
0.29%
Alumni Capital Management LLC
0.26%
Other
91.33%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
6.08%
Investment Advisor
1.50%
Individual Investor
1.39%
Research Firm
0.23%
Other
90.81%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
38
214.66K
2.00%
+60.11K
2025Q3
38
172.48K
10.65%
+130.03K
2025Q2
38
284.07K
17.55%
+238.97K
2025Q1
39
31.11K
2.29%
-13.78K
2024Q4
39
333.53K
5.24%
-391.82K
2024Q3
37
220.02K
0.81%
-322.92K
2024Q2
32
329.65K
0.99%
-162.64K
2024Q1
33
37.63K
1.43%
-462.76K
2023Q4
33
488.86K
18.54%
+447.75K
2023Q3
33
24.22K
1.03%
-36.82K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Chernett (Jorey)
137.20K
1.28%
+137.20K
--
Jun 11, 2025
Dauntless Investment Group, LLC
118.14K
1.1%
+2.37K
+2.05%
Sep 30, 2025
Alumni Capital Management LLC
28.41K
0.26%
+28.41K
--
Sep 23, 2025
Barclays Capital Inc.
24.00K
0.22%
--
--
Sep 30, 2025
Rockefeller Capital Management
10.70K
0.1%
+10.70K
--
Sep 30, 2025
Friend (John E II)
8.00K
0.07%
+8.00K
--
Sep 23, 2025
Coffey (Steven Roy Stent)
1.98K
0.02%
+1.98K
--
Sep 23, 2025
Carmine (Bryce)
1.71K
0.02%
+1.71K
--
Sep 23, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Apr 01, 2025
Merger
5→1
Mar 06, 2025
Merger
5→1
Mar 06, 2025
Merger
5→1
Mar 06, 2025
Merger
5→1
Oct 15, 2024
Merger
10→1
Oct 15, 2024
Merger
10→1
Date
Ex-dividend Date
Type
Ratio
Apr 01, 2025
Merger
5→1
Mar 06, 2025
Merger
5→1
Mar 06, 2025
Merger
5→1
Mar 06, 2025
Merger
5→1
Oct 15, 2024
Merger
10→1
Oct 15, 2024
Merger
10→1
Oct 15, 2024
Merger
10→1
Oct 15, 2024
Merger
10→1
